Inhaled corticosteroids in COPD: quantifying risks and benefits | Thorax
Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial - Respiratory Medicine
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone co | COPD
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results | European Respiratory Society
Overuse of inhaled corticosteroids in COPD: five questions for withdra | COPD
PREVENTING COPD EXACERBATIONS - ppt download
State-of-the-Art Overview of COPD and its Management
preventable and treatable disease - ppt download
The mean annual exacerbation rates of COPD in torch study | Download Scientific Diagram
Inhaled therapy reduces COPD mortality | European Respiratory Society
Long-term outcomes following first short-term clinically important deterioration in COPD | Respiratory Research | Full Text
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease | NEJM
The TORCH (TOwards a Revolution in COPD Health) survival study protocol | European Respiratory Society
Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan | Scientific Reports
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study | Respiratory Research | Full Text
PPT - GOLD Website Address PowerPoint Presentation, free download - ID:4346031
Proportions of patients experiencing CIDs in the TORCH study. CID,... | Download Scientific Diagram
Frontiers | Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?
Change in rate of decline in Fev 1 in UPLIFT ® and TOrCH, including... | Download Scientific Diagram
Methods for therapeutic trials in COPD: lessons from the TORCH trial | European Respiratory Society
JCM | Free Full-Text | Diagnosis and Treatment of Early Chronic Obstructive Lung Disease (COPD) | HTML
PDF) Health status in the TORCH study of COPD: Treatment efficacy and other determinants of change
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease | NEJM
Time to all-cause mortality based on CID status in TORCH (a) and... | Download Scientific Diagram
Time to first (a) moderate/severe exacerbation, (b) exacerbation... | Download Scientific Diagram
